This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Tiagabine

Authoring team

Tiagabine has been licensed as an add-on agent in the treatment of partial seizures, with or without secondary generalisation not satisfactorily controlled with other antiepileptic medication.

Tiagabine has a short elimination half-life (5-9 hours) which can be shortened further (2-4 hours) in patients taking enzyme-inducing drugs such as carbamazepine (1).

Tiagabine works by inhibiting the reuptake of GABA into neurones and glia.

  • has also been used to treat anxiety disorders and neuropathic pain (including fibromyalgia)
    • for anxiety and neuropathic pain, tiagabine is used primarily to augment other treatments
    • tiagabine may be used alongside SSRIs, SNRIs or benzodiazepines for anxiety, or antidepressants, gabapentin, anticonvulsants or opiates for neuropathic pain (2)

The summary of product characteristics should be consulted before prescribing this drug.

Reference:

  • Drug and Therapeutics Bulletin (2000), 38 (6), 47-48.
  • Stahl, S. Stahl's Essential Psychopharmacology: Prescriber's Guide. Cambridge University Press: New York, NY. 2009. pp. 523-526

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.